Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss

Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company

RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining a Outperform rating.

"We believe this quarter is marking the emergence of SRPT as a full-fledged gene therapy company and leader in neuro GT drug... More

Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen

Cowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.

Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More

Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust

SunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary results from a Phase I/IIa MYO-101 study in Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) or beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss,... More

Sarepta Therapeutics (SRPT) Announces Positive Expression, Biomarker Data from Three-Patient Cohort Dosed in MYO-101 Gene Therapy Trial to Treat LGMD2E, or Beta-Sarcoglycanopathy

In two-month post-treatment muscle biopsies, clinical trial participants showed a mean of 51% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 20% measure for success --Robust expression was also quantified by Western Blot and via intensity on IHC 90% mean creatine kinase (CK) reduction from baseline --Participants received a dose of 5x1013 vg/kg --

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from three Limb-girdle muscular dystrophy (LGMD) Type 2E clinical trial... More

Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing

Sarepta Therapeutics (NASDAQ: SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing

Sarepta Therapeutics (SRPT) Exercises Option to Acquire Myonexus Therapeutics

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for five LGMDs: LGMD2E, LGMD2D, LGMD2B, LGMD2C and LGMD2L. Subject to satisfaction of closing conditions, Sarepta will pay the Myonexus shareholders $165 million.

LGMDs represent a group of distinct genetic neuromuscular diseases with a generally common set of symptoms, including progressive, debilitating weakness and wasting that begins in muscles... More

BTIG Expects Sarepta Therapeutics (SRPT) To Pop On Competitor Acquisition

BTIG analyst, Timothy Chiang, reiterated his Buy rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) and believes shares will get a lift on news of Roche (OTC: RHHBY) acquiring Spark Therapeutics (NASDAQ:... More